Benoît Polack1, Thierry Calvez2, Hervé Chambost3, Chantal Rothschild4, Jenny Goudemand5, Ségolène Claeyssens6, Annie Borel-Derlon7, Isabelle Bardoulat8, Frédérique Maurel8, Marie-Christine Woronoff-Lemsi9. 1. Department of Hematology, University Hospital, and CNRS UMR5525, Grenoble-Alpes University, Grenoble, France. 2. Sorbonne University, UPMC University of Paris 06, INSERM, UMR-S 1136, Pierre Louis Institute of Epidemiology and Public Health, Paris, France. 3. APHM, Department of Pediatric Hematology, Children Hospital La Timone, and INSERM, UMR 1062, Aix-Marseille University, Marseille, France. 4. Regional Hemophilia Center, Department of Hematology, University Hospital Necker Enfants Malades, Paris, France. 5. Department of Hematology-Transfusion, University Hospital, Lille, France. 6. Regional Hemophilia Center, Purpan Hospital, Toulouse, France. 7. Regional Hemophilia and VWD Center, University Hospital, and INSERM U919, Caen, France. 8. Department of Health Economics and Outcome Research, IMS Health, La Défense, France. 9. Pharmacy, University Hospital, and INSERM UMR1098, Franche-Comté University, Besançon, France.
Abstract
BACKGROUND: EQOFIX is a medicoeconomic study that analyzed the health-related quality of life (HRQoL) and costs of care of the moderate and severe forms of hemophilia B, treated on demand or by prophylaxis with either plasma-derived Factor IX (pdFIX) or recombinant FIX (rFIX). STUDY DESIGN AND METHODS: The primary objectives were evaluations of the impact of hemophilia B on HRQoL and of the costs associated with its management. The secondary objectives were evaluations of the clinical efficacy and costs of care of pdFIX and rFIX. In this observational study we included and followed for 1 year severe and moderate hemophilia B patients without inhibitor. HRQoL was evaluated through generic and disease-specific questionnaires. Information on the health resources consumed was collected every 3 months. RESULTS: The EQOFIX cohort was composed of 155 patients, including 51 children and 104 adults, with 114 having severe disease and 41 having moderate disease. The regimens were prophylactic for 61 and on demand for 94. Altogether, 78 were treated with rFIX and 77 with pdFIX. There was no difference in the QoL between the pdFIX and rFIX treatments. The extra cost of prophylaxis was €22,605 per bleeding event prevented. The consumption of FIX was 1.4-fold higher for the patients treated with rFIX than for the patients treated with pdFIX. CONCLUSION: Our findings in a cohort composed of 25% of the French population of moderate and severe hemophilia B patients show, with similar clinical and HRQoL results, that treatment with rFIX is more expensive than treatment with pdFIX.
BACKGROUND:EQOFIX is a medicoeconomic study that analyzed the health-related quality of life (HRQoL) and costs of care of the moderate and severe forms of hemophilia B, treated on demand or by prophylaxis with either plasma-derived Factor IX (pdFIX) or recombinant FIX (rFIX). STUDY DESIGN AND METHODS: The primary objectives were evaluations of the impact of hemophilia B on HRQoL and of the costs associated with its management. The secondary objectives were evaluations of the clinical efficacy and costs of care of pdFIX and rFIX. In this observational study we included and followed for 1 year severe and moderate hemophilia Bpatients without inhibitor. HRQoL was evaluated through generic and disease-specific questionnaires. Information on the health resources consumed was collected every 3 months. RESULTS: The EQOFIX cohort was composed of 155 patients, including 51 children and 104 adults, with 114 having severe disease and 41 having moderate disease. The regimens were prophylactic for 61 and on demand for 94. Altogether, 78 were treated with rFIX and 77 with pdFIX. There was no difference in the QoL between the pdFIX and rFIX treatments. The extra cost of prophylaxis was €22,605 per bleeding event prevented. The consumption of FIX was 1.4-fold higher for the patients treated with rFIX than for the patients treated with pdFIX. CONCLUSION: Our findings in a cohort composed of 25% of the French population of moderate and severe hemophilia Bpatients show, with similar clinical and HRQoL results, that treatment with rFIX is more expensive than treatment with pdFIX.
Authors: Paolo A Cortesi; Lucia S D'Angiolella; Alessandra Lafranconi; Mariangela Micale; Giancarlo Cesana; Lorenzo G Mantovani Journal: Pharmacoeconomics Date: 2018-03 Impact factor: 4.981
Authors: Wolfgang Miesbach; Karina Meijer; Michiel Coppens; Peter Kampmann; Robert Klamroth; Roger Schutgens; Marco Tangelder; Giancarlo Castaman; Joachim Schwäble; Halvard Bonig; Erhard Seifried; Federica Cattaneo; Christian Meyer; Frank W G Leebeek Journal: Blood Date: 2017-12-15 Impact factor: 22.113
Authors: Elisabeth A Spronck; Ying Poi Liu; Jacek Lubelski; Erich Ehlert; Sander Gielen; Paula Montenegro-Miranda; Martin de Haan; Bart Nijmeijer; Valerie Ferreira; Harald Petry; Sander J van Deventer Journal: Mol Ther Methods Clin Dev Date: 2019-09-26 Impact factor: 6.698
Authors: Zhengwei Huang; Stephen Nicholas; Yong Yang; Xiaoping Chen; Elizabeth Maitland; Yong Ma; Xuefeng Shi Journal: BMC Health Serv Res Date: 2022-02-19 Impact factor: 2.655